591 related articles for article (PubMed ID: 24067398)
1. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
3. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.
Rudnicki SA; Berry JD; Ingersoll E; Archibald D; Cudkowicz ME; Kerr DA; Dong Y
Amyotroph Lateral Scler Frontotemporal Degener; 2013 Jan; 14(1):44-51. PubMed ID: 22985432
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Cudkowicz M; Genge A; Maragakis N; Petri S; van den Berg L; Aho VV; Sarapohja T; Kuoppamäki M; Garratt C; Al-Chalabi A;
Lancet Neurol; 2021 Oct; 20(10):821-831. PubMed ID: 34536404
[TBL] [Abstract][Full Text] [Related]
9. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R;
Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667
[TBL] [Abstract][Full Text] [Related]
11. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
12. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.
Bozik ME; Mitsumoto H; Brooks BR; Rudnicki SA; Moore DH; Zhang B; Ludolph A; Cudkowicz ME; van den Berg LH; Mather J; Petzinger T; Archibald D
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):406-13. PubMed ID: 25125035
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
[TBL] [Abstract][Full Text] [Related]
14. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
Shibuya K; Misawa S; Kimura H; Noto Y; Sato Y; Sekiguchi Y; Iwai Y; Mitsuma S; Beppu M; Watanabe K; Fujimaki Y; Tsuji Y; Shimizu T; Mizuno T; Nakagawa M; Sawaguchi K; Hanaoka H; Kuwabara S
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):353-8. PubMed ID: 25960085
[TBL] [Abstract][Full Text] [Related]
15. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
[TBL] [Abstract][Full Text] [Related]
16. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Cudkowicz M; Bozik ME; Ingersoll EW; Miller R; Mitsumoto H; Shefner J; Moore DH; Schoenfeld D; Mather JL; Archibald D; Sullivan M; Amburgey C; Moritz J; Gribkoff VK
Nat Med; 2011 Nov; 17(12):1652-6. PubMed ID: 22101764
[TBL] [Abstract][Full Text] [Related]
17. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
19. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
20. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
